Core Insights - The top 20 global biopharmaceutical companies saw a 4% increase in combined market capitalisation from $3.7 trillion on June 30, 2025, to $3.8 trillion on September 30, 2025, despite challenges from tariffs and drug pricing pressures [1] Company Performances - UCB experienced the largest market capitalisation growth of 40.9%, reaching $59.8 billion in Q3 2025, driven by the competitive positioning of its drug Bimzelx in hidradenitis suppurativa [2] - Alnylam Pharmaceuticals recorded a 40.6% increase in market capitalisation, attributed to strong sales of its RNAi therapeutic Amvuttra, which saw a 59% quarter-on-quarter increase in global sales to $492 million in Q2 2025 [3] - AbbVie reported a 24.7% rise in market capitalisation, bolstered by its $2.1 billion acquisition of Capstan Therapeutics and plans to invest $195 million in a new manufacturing facility in North Chicago [4] - Johnson & Johnson's market capitalisation grew by 21.5%, supported by a 5.8% sales growth in Q2 and FDA approval of its monoclonal antibody Tremfya for paediatric patients [5]

Core Viewpoint - Arrowhead Pharmaceuticals has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference therapeutic aimed at treating tauopathies, including Alzheimer's disease, which is a leading cause of cognitive and functional decline [1] Company Summary - Arrowhead Pharmaceuticals, Inc. is focused on developing RNAi therapeutics, with ARO-MAPT being a key investigational product targeting tauopathies [1] - The company is seeking regulatory approval to begin clinical trials, indicating progress in its research and development efforts [1] Industry Summary - Tauopathies, particularly Alzheimer's disease, represent a significant area of concern in neurodegenerative diseases, highlighting the need for innovative treatment options [1] - The announcement reflects ongoing advancements in the field of RNA interference therapies, which may offer new avenues for addressing complex neurological conditions [1]